Protalix BioTherapeutics (PLX) Reports Q2 Loss of $0.11/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Protalix BioTherapeutics Reports Second Quarter 2016 Financial Results
August 8, 2016 4:31 PM EDTPatient Screening Underway for Fabry Phase III Clinical Trial
Data from the Cystic Fibrosis Phase II Clinical Trial Expected Around Year-End
CARMIEL, Israel, Aug. 08, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT: PLX) (TASE: PLX), today announced financial results for the fiscal quarter ended June 30, 2016.
We remain focused on developing our clinical assets, and now have three drugs being evaluated in clinical trials, said Moshe Manor, Protalixs President and Chief Executive Officer. Â We are currently screening patients in our phase... More
